CC 90001

Drug Profile

CC 90001

Alternative Names: CC90001

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator Celgene Corporation
  • Class Anti-inflammatories; Antifibrotics
  • Mechanism of Action Mitogen-activated protein kinase 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatic fibrosis; Idiopathic pulmonary fibrosis

Most Recent Events

  • 06 Feb 2017 Celgene completes a phase I trial in Idiopathic pulmonary fibrosis in USA and Australia (NCT02510937)
  • 09 Jan 2017 Celgene plans a phase IIa trial for Idiopathic pulmonary fibrosis (NCT03142191)
  • 01 Aug 2015 Celgene initiates a phase I trial in Idiopathic pulmonary fibrosis in USA (NCT02510937)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top